A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) (NCT07101328)
BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (51 Sites)
Showing the first 25 of 51 sites.
- City of Hope — Duarte, California
- University of Colorado Denver - School of Medicine - Anschutz Medical Campus — Aurora, Colorado
- Colorado Blood Cancer Institute — Denver, Colorado
- Yale University School of Medicine - Yale Cancer Center — New Haven, Connecticut
- The University of Chicago Medical Center (UCMC) — Chicago, Illinois
- University of Iowa — Iowa City, Iowa
- University of Kansas Cancer Center — Kansas City, Kansas
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Mayo Clinic - Rochester — Rochester, Minnesota
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- New York University (NYU) Clinical Cancer Center — New York, New York
- Weill Cornell Medicine — New York, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
- Cleveland Clinic — Cleveland, Ohio
- University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania
- SCRI Oncology Partners — Nashville, Tennessee
- University of Texas Southwestern — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Intermountain Healthcare — Salt Lake City, Utah
- Swedish Cancer Institute (SCI) — Seattle, Washington
- Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
- The Alfred Hospital — Melbourne, VIC,
- Linear Clinical Research — Nedlands,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, Non-Hodgkin
- NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers — Denver, Colorado
- A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) — Duarte, California
- A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) — Santa Monica, California
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma — Duarte, California
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma — St Louis, Missouri
- A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma — Pasadena, California
Explore by condition: All Lymphoma, Non-Hodgkin clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.